Results 171 to 180 of about 30,028 (235)

Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia. [PDF]

Sci Rep
Woźniak E, Broncel M, Woźniak A, Satała J, Pawlos A, Bukowska B, Gorzelak-Pabiś P.   +6 more
europepmc   +1 more source

Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia.

Journal of Clinical Lipidology, 2017
G. Hovingh, F. Raal, R. Dent, C. Stefanutti, O. Descamps, L. Masana, Armando Lira, I. Bridges, B. Coll, D. Sullivan   +9 more
semanticscholar   +1 more source

Clinical Impact of Lipoprotein (a) and Cumulative Low-Density Lipoprotein Cholesterol Exposure on Coronary Artery Disease in Patients with Heterozygous Familial Hypercholesterolemia. [PDF]

J Atheroscler Thromb
Shishikura D, Harada-Shiba M, Michikura M, Fujioka S, Fujisaka T, Morita H, Kanzaki Y, Hoshiga M.   +7 more
europepmc   +1 more source

P5.22 CAROTID AND AORTIC STIFFNESS IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Artery Research, 2011
A.I. Ershova, A.N. Meshkov, T.A. Rozhkova, A.N. Rogoza, T.V. Balakhonova, S.A. Boytsov   +5 more
doaj   +1 more source

Biochemical and Anthropometric Outcomes in Paediatric Patients with Heterozygous Familial Hypercholesterolemia after COVID-19 Pandemic Lockdowns: An Exploratory Analysis. [PDF]

Nutrients
Peres M, Moreira-Rosário A, Padeira G, Gaspar Silva P, Correia C, Nunes A, Garcia E, Faria A, Teixeira D, Calhau C, Pereira-da-Silva L, Ferreira AC, Rocha JC.   +12 more
europepmc   +1 more source

Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemia.

Journal of Clinical Lipidology, 2017
A. Gallo, P. Giral, A. Carrié, V. Carreau, S. Béliard, R. Bittar, M. Maranghi, M. Arca, P. Cluzel, A. Redheuil, E. Bruckert, D. Rosenbaum   +11 more
semanticscholar   +1 more source

† Safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia

Journal of Clinical Lipidology
Andy Hsieh, Stephen Nicholls, Adam J Nelson, Marc Ditmarsch, John J.P. Kastelein, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Navar, Steven E. Nissen, Anne C. Goldberg, Liam R. Brunham, Erin Wuerdeman, Annie Neild, Douglas Kling, Brian A. Ference, Ulrich Laufs, Maciej Banach, Roxana Mehran, Alberico L. Catapano, Michael H. Davidson   +19 more
openaire   +1 more source

Pediatric implications of heterozygous familial hypercholesterolemia

, 2003
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Heterozygous familial hypercholesterolemia: prevalence and control rates

Expert Review of Endocrinology and Metabolism, 2021
Introduction: Heterozygous familial hypercholesterolemia (heFH) is associated with a very high risk for cardiovascular events. Treatment with potent statins substantially reduces cardiovascular morbidity in these patients. Moreover, combination therapy with statins plus ezetimibe and/or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors ...
Georgios Polychronopoulos, Konstantinos Tziomalos   +1 more
exaly   +4 more sources